A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

Inclusion Criteria * Chinese participants aged ≥18. * Diagnosis of chronic, stable moderate to severe plaque PsO for ≥ 12 months before screening. The participant must have sPGA score ≥ 3, PASI score ≥ 12, and BSA involvement ≥ 10% at both screening and baseline (week 0). * Participant is a candidate for phototherapy and/or systemic therapy. Exclusion Criteria * Psoriasis flare within 4 weeks of screening. * Evidence of skin conditions that would interfere with evaluations of the effect of study medication on psoriasis. * Prior medical history of suicide attempt at any time in the participant's lifetime before screening or randomization, or major psychiatric illness requiring hospitalization within the last 3 years. * Participant has a malignancy or history of malignancy or myeloproliferative or lymphoproliferative disease within the past 3 years. * Active tuberculosis or a history of incompletely treated tuberculosis. * History of human immunodeficiency virus (HIV) infection. * Prior treatment with apremilast. * Female participants of childbearing potential unwilling to use protocol specified method of contraception. * Female participants who are breastfeeding or who plan to breastfeed. * Female participants planning to become pregnant.